Improving Radiotherapy Plan Quality for Nasopharyngeal Carcinoma With Enhanced UNet Dose Prediction

利用增强型UNet剂量预测提高鼻咽癌放射治疗计划质量

阅读:2

Abstract

BACKGROUND: Individualized dose prediction is critical for optimizing radiation treatment planning. This study introduces DESIRE, an enhanced UNet-based dose prediction model with progrEssive feature fuSion and dIfficult Region lEarning, tailored for nasopharyngeal carcinoma (NPC) patients receiving volumetric modulated arc therapy. We aimed to assess the impact of integrating DESIRE into the treatment planning process to improve plan quality. METHODS: This retrospective study included 131 NPC patients diagnosed at Jiangxi Cancer Hospital between 2017 and 2020. Twenty patients were randomly allocated to a testing cohort, while the remaining 111 comprised a training cohort. Target delineation included three planning target volumes (PTVs): PTV70, PTV60, and PTV55, along with several organs at risk (OARs). The DESIRE model predicted dose distributions, and discrepancies between DESIRE's predictions and the ground truth (GT) were quantified using dosimetric metrics and gamma pass rates. Two junior physicians used DESIRE's predictions for treatment planning, and their plans were compared to the GT. RESULTS: Most of DESIRE's predicted dosimetric metrics closely aligned with GT (mean difference < 1 Gy), with no significant differences (p > 0.05) in D(mean) and D(1) values across OARs. While significant differences were observed in PTV metrics, the mean differences in D(98), D(95), D(50), and D(mean) between DESIRE and GT did not exceed 1 Gy. Assisted by DESIRE, the junior physicians' plans were comparable to the GT in nearly all OARs, with no significant differences in dosimetric metrics. The conformity index (CI) and homogeneity index (HI) for PTV70 surpassed the GT (0.847 ± 0.036 vs. 0.827 ± 0.037 for CI, and 0.057 ± 0.009 vs. 0.052 ± 0.008 for HI). The average three-dimensional gamma passing rates were 0.85 for PTV70 and 0.87 for the 35-Gy isodose line. CONCLUSIONS: The DESIRE model shows promise for patient-specific dose prediction, enhancing junior physicians' treatment planning capabilities and improving plan quality.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。